Audited Supplier
Lenisna
Lenisna
1 Box
Collagen
Within 7 Days
OEM
Box
200mg/Vial
South Korea
Product Description
| Name | Lenisna | Country of origin | South Korea |
| Form | Powder | Package | 200mg/1vial |
Lenisna 1x200mg
The LENISNA product was designed as a filler that acts over time, with a concentration of 170 mg of polylactic acid PDLLA and 30 mg of non-cross-linked hyaluronic acid.
By adjusting the amount of solution and the particle size from 50 to 60 micrometers and combining them with non-cross-linked hyaluronic acid, a hybrid was obtained adapted for application into the subcutaneous tissue or periosteum.
It is intended for the treatment of deep wrinkles, laxity and significant tissue defects.
Lenisna stimulates the production of collagen, which is responsible for skin firmness and tension. Thanks to this, we obtain the effect of young and firm skin.
Lenisna is a combination of polylactic acid PDLLA and hyaluronic acid HA, thanks to which we obtain an effect visible immediately after the treatment.
The filling lasts until the production of new collagen by poly D,L lactic acid begins to dominate.
Lenisna has the ability to strongly and long-lastingly stimulate collagen production and restore a youthful appearance, gradually and naturally.
Indications
The product is intended for intradermal and subcutaneous implantation to fill skin cavities to restore and increase the volume of soft tissue.
It is recommended to be used for reconstructive purposes in the treatment of morphological asymmetry.
Areas
Facial area
Inner thighs
Belly
Buttocks
Saggy arms
Characteristics
The world's only Poly D,L Lactyd + HA hybrid formula, with a particle size of 50 to 60 micrometers
Efficacy and safety confirmed by clinical trials
Durability of effects - over 2 years from the last treatment
Immediate effect - due to hyaluronic acid
Safety - FDA, CE certificates for polylactic acid
Patents and own clinical trials
Particle size from 50 to 60 micrometers
Comfort of the procedure - easy injection and no needle clogging during the procedure
Patents
Patent: No. 10-1481441 - method of producing polymer microparticles with a network structure, which allows for connection with non-cross-linked hyaluronic acid, which is a carrier for PDLLA acid
Patent: No. 10-1725279 - process of obtaining polylactic acid microparticles by spraying, spherical, porous shape.
Areas:
Cheeks
Jaw
Nasolabial folds
Corners of the mouth
Infraorbital area
Deep wrinkles
Composition
170 mg of PDLLA polylactic acid
30 mg of non-cross-linked hyaluronic acid
What makes LENISNA unique?
Its ability to most strongly stimulate collagen production and restore a youthful appearance, gradually and naturally.
No need to massage post-treatment areas due to the round shape of PDLLA molecules and its combination with non-cross-linked hyaluronic acid.
The durability of the treatment lasts over 24 months. The effect can be maintained by performing 1 repeat treatment after 24 months.
Effects of therapy
The effects of the therapy are visible immediately after administration. We achieve a filling effect thanks to the presence of hyaluronic acid.
After about 2 weeks, collagen production begins by the presence of PDLLA lactic acid microparticles.
The effects of the therapy last over two years after the last treatment.
The recommended number of treatments is 2 or 3, depending on the skin defect, at 6-8 week intervals. After two years, we recommend performing 1 repeat treatment.
Use
Preparation of the preparation: Add 5 ml of sterile water for injection to the vial. Place the preparation in a VORTEX laboratory shaker. After 30 minutes, the preparation is ready for use.
The preparation in an amount of 5 ml is administered using a cannula of size 22 to 25G or needles of size 25-26G.
It is applied to the subcutaneous tissue.
CONTRAINDICATIONS
Pregnancy
Breast-feeding
Active infection
Collagen diseases
Active, unregulated autoimmune diseases
Allergy to the ingredients of the preparation
Inflammation of the skin in the area of the planned procedure
The product is intended for use by a professional.
